CATX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Perspective Therapeutics Inc (CATX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks immediate positive catalysts, has shown a significant regular market price drop (-8.83%), and its financial performance reflects declining revenue. While analysts have a positive long-term outlook with price targets significantly above the current price, the lack of recent news, weak technical indicators, and no immediate trading signals suggest holding off on buying right now.
The technical indicators show mixed signals. The MACD is negative and expanding downward, indicating bearish momentum. The RSI is neutral at 45.049, and while the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock has recently dropped below key pivot levels. Support levels are at 4.704 and 4.381, while resistance levels are at 5.751 and 6.074.
Analysts have a positive long-term outlook with price targets of $12 and $16, citing the company's promising pipeline of radiotherapies and reduced competition in the market.
Gross margin remains strong at 100%.
The company reported a significant revenue decline (-43.36% YoY) in Q3
The stock experienced a sharp regular market price drop (-8.83%) and a slight pre-market decline (-1.21%).
No recent news or congress trading data to act as a catalyst.
Options data shows a high put-call volume ratio (32.67), indicating bearish sentiment.
In Q3 2025, the company's revenue dropped by 43.36% YoY to $209,000, but net income improved to -$25.97M, up 71.73% YoY. EPS also improved to -0.35, up 66.67% YoY. Gross margin remains at 100%, but the revenue decline raises concerns about growth.
Analysts have a positive long-term outlook on CATX. Piper Sandler initiated coverage with an Overweight rating and a $16 price target, citing the company's promising pipeline of radiotherapies. H.C. Wainwright raised its price target to $12 from $10, highlighting reduced competition as a positive factor.
